Nubratori RX, started just after the enactment of the Drug Quality and Securities Act of 2013 by Congress. Nubratori RX spent its first four years in research and development, testing, and validating potential new products as requested by providers. 2017 brought the launch of Nubratori RX’s first production run. To date, Nubratori RX has produced closed to 250,000 units of products, and counting, with zero adverse reports. After emerging from the COVID-19 pandemic, Nubratori RX continues to serve patients, providers, and clinics.

 

Nubratori RX, under its FDA Registration for Outsourcing Facilities, compounds and manufactures sterile and non-sterile medications requested by providers for having a clinical significance to meet patient's needs over other commercially available products on the market. 

 

If you are a hospital administrator, pharmacist, or physician and would like to find out more, please contact us.